Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Curcumin, the active compound in turmeric (Curcuma longa), has gained attention for its potential benefits in managing colitis, particularly ulcerative colitis and inflammatory bowel disease (IBD). Several clinical and preclinical studies suggest that curcumin exhibits significant anti-inflammatory properties, primarily by inhibiting the NF-κB pathway and reducing the production of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. This mechanistic action underpins its potential therapeutic effect in colitis, a condition characterized by chronic inflammation of the colon.

A number of randomized controlled trials (RCTs) have evaluated curcumin as an adjunct therapy in patients with mild-to-moderate ulcerative colitis. For example, a 2006 double-blind, placebo-controlled study (Hanai et al.) demonstrated that curcumin, given alongside standard mesalamine therapy, significantly reduced relapse rates and improved symptom scores compared to placebo over a six-month period. Systematic reviews and meta-analyses of such trials generally conclude that curcumin is safe and may provide a moderate benefit in maintaining remission or reducing disease activity, though results are occasionally mixed and more large-scale studies are warranted.

Overall, the evidence supporting curcumin’s use in colitis is moderate (score 3/5). While its anti-inflammatory effects are well-documented in laboratory and animal studies, and early clinical trials are promising, larger and longer-term human studies are needed to establish definitive efficacy and optimal dosing.

More about curcumin
More about Colitis

Other ingredients used for Colitis

Other health conditions supported by curcumin

Products containing curcumin

Nature's Sunshine Turmeric Curcumin (Formerly CurcuminBP)